Celsion Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Celsion Corporation for the period ended September 30, 2006. Celsion is a biotechnology company focused on oncology drugs and tumor-targeting treatments using focused heat energy. Its primary commercial product is the Prolieve Thermodilatation system for treating Benign Prostatic Hyperplasia (BPH), distributed exclusively by Boston Scientific Corporation. The company is also developing ThermoDox, a heat-activated liposomal encapsulation of doxorubicin for liver and breast cancer.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Net Sales | $4,122,908 | $6,775,117 |
| Gross Margin | $2,219,764 (53.9%) | $2,465,598 (36.4%) |
| Net Loss | $(991,148) | $(6,497,468) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.61) |
| Cash and Cash Equivalents | $1,872,878 | $1,872,878 (Balance Sheet) |
| Short-Term Investments | $8,500,000 | $8,500,000 (Balance Sheet) |
| Total Current Assets | $16,586,579 | $16,586,579 (Balance Sheet) |
| Total Current Liabilities | $3,507,832 | $3,507,832 (Balance Sheet) |
| Working Capital | $13,078,747 | $13,078,747 (Balance Sheet) |
| Long-Term Debt (Loan Payable) | $15,000,000 | $15,000,000 (Balance Sheet) |
| Accumulated Deficit | $(89,400,052) | $(89,400,052) (Balance Sheet) |
Material Changes vs. Prior Period
- Revenue: Net sales increased 29% in the quarter ($4.12M vs. $3.21M) due to inventory rebuilding by Boston Scientific following a product recall. However, for the nine-month period, sales decreased 15% ($6.78M vs. $7.97M) due to a supply interruption caused by a Class II recall of disposable catheter kits between July and August 2006.
- Gross Margin: Quarterly gross margin improved significantly to 53.9% from 31.8% in the prior year quarter, driven by cost reductions from a new catheter kit supplier. Year-to-date margin was 36.4%, lower than the current quarter due to costs associated with scrapping recalled products.
- Operating Expenses: Research and Development (R&D) expenses remained relatively flat quarter-over-quarter but included significant new stock-based compensation expenses due to the adoption of SFAS 123(R). General and Administrative (G&A) expenses increased slightly.
- Net Loss: The quarterly net loss decreased by 49% to $991,148 compared to $1.95M in the prior year. The nine-month net loss was $6.50M, nearly flat compared to $6.56M in the prior year, largely due to a one-time gain of $1.01M on the sale of Celsion (Canada) Limited offset by increased interest expenses and recall costs.
- Debt: The company fully funded a $15 million loan facility from Boston Scientific, with the final installment of $4.5 million disbursed in July 2006. Accrued interest payable increased to $923,115.
Guidance, Outlook, and Risks
- Management Commentary: Management expects revenues to continue from Prolieve sales in the near term. Long-term revenue is anticipated from licensing targeted drug delivery technologies developed with Duke University. The company estimates expending approximately $10 million in fiscal 2006 for commercialization and clinical testing.
- Executive Changes: Lawrence Olanoff, M.D., Ph.D., resigned as President and CEO effective October 6, 2006. Anthony P. Deasey was named Interim President and CEO.
- Legal Proceedings: American Medical Systems (AMS) filed a patent infringement lawsuit regarding the Prolieve system. The initial suit in Minnesota was dismissed for lack of jurisdiction, but a new suit was filed in Delaware on September 28, 2006. Legal expenses incurred for the nine months ended September 30, 2006, totaled $543,365. An escrow account established with Boston Scientific is being used to fund these legal costs.
- Listing Compliance: The company received notice from the American Stock Exchange (AMEX) regarding non-compliance with listing standards due to shareholder equity levels and net losses. A compliance plan was accepted, granting an extension until December 14, 2007, to regain compliance.
- Accounting Changes: The adoption of SFAS 123(R) regarding share-based payments resulted in a significant increase in compensation expense, estimated at $1.0 million to $1.75 million for the full year 2006.
Investor Verification Checklist
- Product Recall Impact: Verify the long-term impact of the Class II catheter kit recall on Boston Scientific's inventory levels and future sales velocity.
- Legal Contingency: Monitor the Delaware patent infringement lawsuit filed by AMS and the sufficiency of the escrow account to cover potential damages or settlements.
- Liquidity Runway: Assess the company's ability to fund operations given the $15M debt obligation (due 2009) and the reliance on Prolieve revenues, which are subject to the Boston Scientific distribution agreement.
- AMEX Compliance: Track progress on the plan to regain compliance with AMEX listing standards to avoid delisting risks.
- Stock-Based Compensation: Review the impact of SFAS 123(R) on future earnings, as this non-cash expense significantly affects reported net loss.